Genmab maintains 2026 revenue guidance, forecasts 19% growth at midpoint

Bitget2026/11/05 18:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab maintained 2026 revenue guidance of USD 4.33 billion to USD 4.53 billion, implying 19% growth at the midpoint.
Adjusted operating profit is forecast at USD 1.07 billion to USD 1.39 billion.
Adjusted operating expenses are projected at USD 2.81 billion to USD 2.95 billion, reflecting accelerated late-stage development and launch preparations.
EPKINLY growth and continued momentum across the royalty portfolio underpin the revenue outlook.
Investment focuses on petosemtamab and Rina-S, with multiple potential launches expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab maintains 2026 revenue guidance, forecasts 19% growth at midpoint

You may also like

Crypto prices